il 17a neutralizing antibodies Search Results


mouse il-17/il-17a antibody  (Bio-Techne corporation)
93
Bio-Techne corporation mouse il-17/il-17a antibody
Mouse Il 17/Il 17a Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse il-17/il-17a antibody/product/Bio-Techne corporation
Average 93 stars, based on 1 article reviews
mouse il-17/il-17a antibody - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
il 17a neutralizing antibody  (BPS Bioscience)
90
BPS Bioscience il 17a neutralizing antibody
Impact of <t>IL-17A</t> on MNs: ( A ) the MAP-2 immunostaining after different concentrations (5 ng/mL, 50 ng/mL, and 500 ng/mL) of IL-17A-stimulated MNs for three days; ( B ) the viability of MNs under the same IL-17A treatment for three days was evaluated using CCK-8 assay; ( C ) the MAP-2 positive MNs, counting manually in different IL-17A treatments; ( D ) the neurite length of MAP-2 positive MNs was calculated using Neuron J in the FIJI software; ( E ) the immunostaining of MAP-2 with the same IL-17A treatment at different times (three days and six days); ( F ) the MAP-2 positive MNs’ counting in IL-17A treatment at different times; ( G ) the length of the neurite was measured under the same treatment. * p < 0.05, ** p < 0.01, *** p < 0.001 versus controls, ns: no significance.
Il 17a Neutralizing Antibody, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 17a neutralizing antibody/product/BPS Bioscience
Average 90 stars, based on 1 article reviews
il 17a neutralizing antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
neutralizing mab to murine il-17a antibody  (Biocell Technology)
90
Biocell Technology neutralizing mab to murine il-17a antibody
Impact of <t>IL-17A</t> on MNs: ( A ) the MAP-2 immunostaining after different concentrations (5 ng/mL, 50 ng/mL, and 500 ng/mL) of IL-17A-stimulated MNs for three days; ( B ) the viability of MNs under the same IL-17A treatment for three days was evaluated using CCK-8 assay; ( C ) the MAP-2 positive MNs, counting manually in different IL-17A treatments; ( D ) the neurite length of MAP-2 positive MNs was calculated using Neuron J in the FIJI software; ( E ) the immunostaining of MAP-2 with the same IL-17A treatment at different times (three days and six days); ( F ) the MAP-2 positive MNs’ counting in IL-17A treatment at different times; ( G ) the length of the neurite was measured under the same treatment. * p < 0.05, ** p < 0.01, *** p < 0.001 versus controls, ns: no significance.
Neutralizing Mab To Murine Il 17a Antibody, supplied by Biocell Technology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/neutralizing mab to murine il-17a antibody/product/Biocell Technology
Average 90 stars, based on 1 article reviews
neutralizing mab to murine il-17a antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti-il-17a neutralizing antibodies  (RD Biotech)
90
RD Biotech anti-il-17a neutralizing antibodies
Impact of <t>IL-17A</t> on MNs: ( A ) the MAP-2 immunostaining after different concentrations (5 ng/mL, 50 ng/mL, and 500 ng/mL) of IL-17A-stimulated MNs for three days; ( B ) the viability of MNs under the same IL-17A treatment for three days was evaluated using CCK-8 assay; ( C ) the MAP-2 positive MNs, counting manually in different IL-17A treatments; ( D ) the neurite length of MAP-2 positive MNs was calculated using Neuron J in the FIJI software; ( E ) the immunostaining of MAP-2 with the same IL-17A treatment at different times (three days and six days); ( F ) the MAP-2 positive MNs’ counting in IL-17A treatment at different times; ( G ) the length of the neurite was measured under the same treatment. * p < 0.05, ** p < 0.01, *** p < 0.001 versus controls, ns: no significance.
Anti Il 17a Neutralizing Antibodies, supplied by RD Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-il-17a neutralizing antibodies/product/RD Biotech
Average 90 stars, based on 1 article reviews
anti-il-17a neutralizing antibodies - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Impact of IL-17A on MNs: ( A ) the MAP-2 immunostaining after different concentrations (5 ng/mL, 50 ng/mL, and 500 ng/mL) of IL-17A-stimulated MNs for three days; ( B ) the viability of MNs under the same IL-17A treatment for three days was evaluated using CCK-8 assay; ( C ) the MAP-2 positive MNs, counting manually in different IL-17A treatments; ( D ) the neurite length of MAP-2 positive MNs was calculated using Neuron J in the FIJI software; ( E ) the immunostaining of MAP-2 with the same IL-17A treatment at different times (three days and six days); ( F ) the MAP-2 positive MNs’ counting in IL-17A treatment at different times; ( G ) the length of the neurite was measured under the same treatment. * p < 0.05, ** p < 0.01, *** p < 0.001 versus controls, ns: no significance.

Journal: International Journal of Molecular Sciences

Article Title: Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs

doi: 10.3390/ijms22158042

Figure Lengend Snippet: Impact of IL-17A on MNs: ( A ) the MAP-2 immunostaining after different concentrations (5 ng/mL, 50 ng/mL, and 500 ng/mL) of IL-17A-stimulated MNs for three days; ( B ) the viability of MNs under the same IL-17A treatment for three days was evaluated using CCK-8 assay; ( C ) the MAP-2 positive MNs, counting manually in different IL-17A treatments; ( D ) the neurite length of MAP-2 positive MNs was calculated using Neuron J in the FIJI software; ( E ) the immunostaining of MAP-2 with the same IL-17A treatment at different times (three days and six days); ( F ) the MAP-2 positive MNs’ counting in IL-17A treatment at different times; ( G ) the length of the neurite was measured under the same treatment. * p < 0.05, ** p < 0.01, *** p < 0.001 versus controls, ns: no significance.

Article Snippet: Further, 0.5 µg/mL of IL-17A neutralizing antibody (1:1,000, BPS Bioscience, San Diego, CA, USA) and 1µg/mL of human IL17RA/IL-17R antibody pretreatment (1:500, R&D Systems, Minneapolis, MN, USA) for 0.5 h prior to adding IL-17A was performed for three days.

Techniques: Immunostaining, CCK-8 Assay, Software

Effect of IL-17F on MNs: ( A ) immunostaining of MAP-2 in IL-17F (5 ng/mL, 50 ng/mL, and 500 ng/mL) stimulated MNs; ( B ) the viability of MNs under different IL-17F treatments was measured using CCK-8 assay; ( C ) MAP-2 positive MNs counting under different IL-17F treatments; (D) the neurite length was calculated, using Neuron J in the FIJI software, under different treatment conditions in both cells, ns: no significance.

Journal: International Journal of Molecular Sciences

Article Title: Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs

doi: 10.3390/ijms22158042

Figure Lengend Snippet: Effect of IL-17F on MNs: ( A ) immunostaining of MAP-2 in IL-17F (5 ng/mL, 50 ng/mL, and 500 ng/mL) stimulated MNs; ( B ) the viability of MNs under different IL-17F treatments was measured using CCK-8 assay; ( C ) MAP-2 positive MNs counting under different IL-17F treatments; (D) the neurite length was calculated, using Neuron J in the FIJI software, under different treatment conditions in both cells, ns: no significance.

Article Snippet: Further, 0.5 µg/mL of IL-17A neutralizing antibody (1:1,000, BPS Bioscience, San Diego, CA, USA) and 1µg/mL of human IL17RA/IL-17R antibody pretreatment (1:500, R&D Systems, Minneapolis, MN, USA) for 0.5 h prior to adding IL-17A was performed for three days.

Techniques: Immunostaining, CCK-8 Assay, Software

Immunostaining of the IL-17 receptor (IL-17RA and IL-17RC) and MHCI in MNs: ( A ) immunostaining of IL-17RA, IL-17RC, and MHCI in FUS-WT-EGFP, FUS-P525L-EGFP, PBMCs, and a fibroblast: ( B ) co-staining of MAP-2 with IL-17RA, IL-17RC, and MHCI in FUS-WT-EGFP and FUS-P525L-EGFP cells; ( C ) the counting of IL-17RA positive cells in MNs; ( D ) IL-17RA positive staining in MNs; ( E ) MHCI positive staining in MNs. * p < 0.05 versus controls, ns: no significance.

Journal: International Journal of Molecular Sciences

Article Title: Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs

doi: 10.3390/ijms22158042

Figure Lengend Snippet: Immunostaining of the IL-17 receptor (IL-17RA and IL-17RC) and MHCI in MNs: ( A ) immunostaining of IL-17RA, IL-17RC, and MHCI in FUS-WT-EGFP, FUS-P525L-EGFP, PBMCs, and a fibroblast: ( B ) co-staining of MAP-2 with IL-17RA, IL-17RC, and MHCI in FUS-WT-EGFP and FUS-P525L-EGFP cells; ( C ) the counting of IL-17RA positive cells in MNs; ( D ) IL-17RA positive staining in MNs; ( E ) MHCI positive staining in MNs. * p < 0.05 versus controls, ns: no significance.

Article Snippet: Further, 0.5 µg/mL of IL-17A neutralizing antibody (1:1,000, BPS Bioscience, San Diego, CA, USA) and 1µg/mL of human IL17RA/IL-17R antibody pretreatment (1:500, R&D Systems, Minneapolis, MN, USA) for 0.5 h prior to adding IL-17A was performed for three days.

Techniques: Immunostaining, Staining

Antagonizing IL17 protects from IL17-induced neurodegeneration: ( A ) IL-17A-neutralizing pretreatment for 0.5 h, 50 ng/mL IL-17A stimulated the MNs for three days, MAP-2 immunostaining was performed after the treatment; ( B ) the viability of MNs under the same treatment mentioned before was calculated using CCK-8 assay; ( C ) MAP-2 positive MNs were counted and (D) the neurite length of MNs were measuredunder different treatments; ( E ) immunostaining of MAP-2 under anti-IL-17RA/IL-17R receptor pretreatment for 0.5 h, then 50 ng/mL IL-17A-stimulated for three days; ( F ) viability of MNs; ( G ) MAP-2 positive MNs counting; (H) neurite length of MAP-2 positive MNs using the aforementioned treatment.* p < 0.05, ** p < 0.01 versus controls, ns: no significance.

Journal: International Journal of Molecular Sciences

Article Title: Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs

doi: 10.3390/ijms22158042

Figure Lengend Snippet: Antagonizing IL17 protects from IL17-induced neurodegeneration: ( A ) IL-17A-neutralizing pretreatment for 0.5 h, 50 ng/mL IL-17A stimulated the MNs for three days, MAP-2 immunostaining was performed after the treatment; ( B ) the viability of MNs under the same treatment mentioned before was calculated using CCK-8 assay; ( C ) MAP-2 positive MNs were counted and (D) the neurite length of MNs were measuredunder different treatments; ( E ) immunostaining of MAP-2 under anti-IL-17RA/IL-17R receptor pretreatment for 0.5 h, then 50 ng/mL IL-17A-stimulated for three days; ( F ) viability of MNs; ( G ) MAP-2 positive MNs counting; (H) neurite length of MAP-2 positive MNs using the aforementioned treatment.* p < 0.05, ** p < 0.01 versus controls, ns: no significance.

Article Snippet: Further, 0.5 µg/mL of IL-17A neutralizing antibody (1:1,000, BPS Bioscience, San Diego, CA, USA) and 1µg/mL of human IL17RA/IL-17R antibody pretreatment (1:500, R&D Systems, Minneapolis, MN, USA) for 0.5 h prior to adding IL-17A was performed for three days.

Techniques: Immunostaining, CCK-8 Assay